{"id":3234,"date":"2026-09-17T09:00:00","date_gmt":"2026-09-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3234"},"modified":"2026-09-19T13:53:11","modified_gmt":"2026-09-19T17:53:11","slug":"fda-approves-fayuvi-for-mps-iiia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3234","title":{"rendered":"FDA Approves Fayuvi for MPS IIIA"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Ultragenyx<\/p>\n

Event Type<\/strong><\/p>\n

FDA Approval<\/p>\n

Modality<\/strong><\/p>\n

One-Time Intravenous AAV9 Gene Therapy<\/p>\n

Asset<\/strong><\/p>\n

Fayuvi (Rebisufligene Etisparvovec-Hopf, Formerly UX111)<\/p>\n

Disease Area<\/strong><\/p>\n

Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)<\/p>\n

Summary<\/h4>\n

FDA approved Fayuvi, a one-time intravenous AAV9 gene therapy, for neurologic manifestations of mucopolysaccharidosis IIIA in pediatric patients with preserved neurodevelopmental function. The approval is the first U.S. treatment for Sanfilippo syndrome type A. The pivotal evidence combines biochemical target correction with developmental outcomes from an open-label, single-arm study compared with external natural-history controls. Approval is a major therapeutic advance, but the small nonrandomized dataset, phenotype heterogeneity, long-term integration risk, and intensive immunosuppression and monitoring requirements constrain the strength and portability of the efficacy inference.<\/p>\n

FDA announced the approval on September 17, 2026; it was recovered in the September 19 reconciliation after the morning package. Fayuvi is rebisufligene etisparvovec-hopf, formerly UX111. Ultragenyx reported a 17-patient modified intent-to-treat group with follow-up approaching eight years. The study evaluated developmental trajectories against untreated natural-history participants and showed a marked reduction in cerebrospinal-fluid heparan sulfate, the accumulated substrate caused by deficient sulfamidase activity.<\/p>\n

The approved dose is 3.0 × 10^13 vector genomes per kilogram as a single intravenous infusion. Corticosteroids begin one day before dosing and continue for at least eight weeks. The prescribing information identifies liver-enzyme elevations, nausea, vomiting, fever, appetite loss, leukopenia, thrombocytopenia, and increased amylase among common adverse reactions. Warnings include thrombotic microangiopathy and a theoretical long-term risk of tumors from vector-genome integration. The company expects product shipment within 30 to 60 days of approval.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that systemic AAV9 delivery achieved clinically meaningful central-nervous-system enzyme replacement and altered the neurodevelopmental course in children treated before substantial irreversible injury. Sustained biochemical correction, lengthy follow-up, and a label restricted to preserved neurodevelopment support that interpretation. Against it, the study is small and nonrandomized, natural-history matching can leave residual confounding, and developmental trajectories in MPS IIIA vary by genotype and baseline disease stage. A second interpretation is that the clearest benefit is concentrated in younger, less-advanced patients with enough neuronal reserve to respond. The label supports this narrower reading, while evidence in older or more impaired children remains insufficient rather than demonstrably negative.<\/p>\n

Company and Product Background<\/h4>\n

MPS IIIA is caused by biallelic SGSH variants that reduce N-sulfoglucosamine sulfohydrolase activity. Heparan sulfate accumulates in lysosomes, driving progressive neurodegeneration, behavioral and sleep disturbance, language loss, and premature death. Fayuvi uses an AAV9 vector to deliver a functional SGSH gene after intravenous infusion. The modality aims for persistent enzyme production and substrate clearance across the central nervous system and peripheral tissues; efficacy depends on early tissue access, adequate transduction, immune management, and durable expression.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Fayuvi establishes the first regulatory proof that a one-time gene-replacement approach can support approval in MPS IIIA.<\/li>\n
  • Upgrades with:<\/strong> durable postmarketing preservation of cognition, language, adaptive function, sleep, mobility, and survival versus prospectively matched natural history; consistent benefit across genotypes; and low rates of serious hepatic, hematologic, immune, and neurologic toxicity.<\/li>\n
  • Downgrades with:<\/strong> waning transgene effect, developmental convergence toward untreated trajectories, frequent thrombotic microangiopathy, persistent cytopenias, or treatment-limiting immune responses.<\/li>\n
  • Falsified if:<\/strong> benefit is confined to a narrow presymptomatic subgroup or if long-term integration-related malignancy or severe organ toxicity outweighs neurologic preservation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Fayuvi establishes the first regulatory proof that a one-time gene-replacement approach can support approval in MPS IIIA. The strongest evidence is the convergence of substrate reduction and longitudinal developmental preservation, not either measure alone. The historical-control design and highly selected treatment window mean approval should not be interpreted as randomized proof or as established benefit in advanced disease.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 5\/5 — first U.S. therapy for MPS IIIA and a new pediatric neurologic gene-therapy approval. Importance:<\/strong> Positive — full approval establishes a treatment option with biochemical and developmental evidence. Confidence:<\/strong> High on facts (FDA and the prescribing information define the indication, dose, evidence, and safety requirements); moderate on interpretation (clinical inference relies on a small single-arm cohort and external natural-history comparison).<\/p>\n","protected":false},"excerpt":{"rendered":"

    FDA approved Fayuvi, a one-time intravenous AAV9 gene therapy, for neurologic manifestations of mucopolysaccharidosis IIIA in pediatric patients with preserved neurodevelopmental function. The approval is the first U.S. treatment for Sanfilippo syndrome type A….<\/p>\n","protected":false},"author":1,"featured_media":3239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[292,795,396],"class_list":["post-3234","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-gene-therapy","tag-mps-iiia","tag-ultragenyx"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3234"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3234\/revisions"}],"predecessor-version":[{"id":3254,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3234\/revisions\/3254"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3239"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}